Evidence on Outcomes After Switching Prospective randomized data specifically on semaglutide-to-tirzepatide switching are limited as of mid-2025
"When you have millions of people using these drugs, you know, a 1% risk still translates to many people who may experience these events," said Dr
Dupilumab Development Program In addition to the currently approved indications, Regeneron and Sanofi are also studying dupilumab in a broad range of clinical development programs for diseases driven by allergic and other type 2 inflammation, including pediatric asthma (6 to 11 years of age, Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 2/3), eosinophilic esophagitis (Phase 3), chronic obstructive pulmonary disease (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), and food and environmental allergies (Phase 2)
At Ishin Beauty, stability, quality, and real-life use are always considered
